Puma Biotechnology Inc. (PBYI) Is Up Sharply As European Approval Looks Likely
Puma Biotechnology Inc. (PBYI) announced Tuesday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive trend vote recommending the approval of neratinib. Neratinib is a treatment for early stage HER2-positive hormone receptor positive breast cancer.
Source: RTTNews